Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. (Q54357790)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. |
scientific article |
Statements
Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin (English)
P Chevallier
A Pigneux
M Hunault
J Delaunay
F Perry
L Lode
S Richebourg
O Blanchet
N Vey
D Blaise
J-L Harousseau
22 October 2009
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference